CAR T cell resistance to oncogenic transformation.

In this commentary we discuss the investigation into reports of T-cell malignancies following CAR T-cell therapy. We argue that while these cases should be thoroughly examined, current data suggests that such risks with autolgous CAR T cells are remarkably low compared to other cancer treatments. We also emphasize the importance of continued research, transparent reporting, and participation in post-authorization safety studies.